Lidocaine reduces canine infarct size and decreases release of a lipid peroxidation product.
Whether and how lidocaine reduced infarct size in a canine model of ischemia and reperfusion was investigated. Twenty dogs underwent a 90-min left anterior descending artery ligation and 300 min of reperfusion. Infarct size was measured by triphenyl tetrazolium chloride and the region at risk by 99Tc-labeled albumin microspheres injected during ischemia. In 10 dogs, lidocaine (70 micrograms/kg/min i.v.) was infused 90 min prior to and during ischemia and reperfusion, while 10 dogs were untreated. The ratio of infarct to risk area was 35.2 +/- 3.4% (SEM) in lidocaine dogs vs. 48.5 +/- 5.3% in untreated dogs (p less than 0.05). Lidocaine did not reduce neutrophil accumulation in ischemic and reperfused myocardium at 5 h of reperfusion, inhibit stimulated neutrophil superoxide production, or scavenge superoxide in vitro. However, during early reperfusion, lidocaine reduced coronary sinus levels of a lipid peroxidation product (conjugated dienes). Thus, clinically relevant lidocaine infusion rates reduced myocardial infarct size when given prior to and during ischemia and reperfusion. This protective effect may be due to lidocaine's membrane stabilizing effects, which could have protected the myocardial cell membrane from lipid peroxidation.
Lesnefsky
E J
EJ
Department of Medicine, University of Colorado Health Sciences Center, Denver 80262.
VanBenthuysen
K M
KM
McMurtry
I F
IF
Shikes
R H
RH
Johnston
R B
RB
Horwitz
L D
LD
D000818:Animals; D002463:Cell Membrane Permeability / Q000187:drug effects; D004285:Dogs; D008012:Lidocaine / Q000494:pharmacology*; D015227:Lipid Peroxidation / Q000187:drug effects*; D009203:Myocardial Infarction / Q000378:metabolism* / Q000503:physiopathology; D015425:Myocardial Reperfusion; D009206:Myocardium / Q000378:metabolism*; D009504:Neutrophils / Q000378:metabolism; D013481:Superoxides / Q000378:metabolism
D013481:Superoxides; D008012:Lidocaine